One-liner#

BPH management requires symptom quantification (AUA-SI score), ruling out mimics (prostate cancer, UTI, OAB), and treatment selection based on symptom severity and prostate size—alpha-blockers for rapid relief, 5-ARIs for large prostates, and combination therapy for significant symptoms with enlarged glands.

Quick nav#

• Definition and epidemiology
• Pathophysiology
• Clinical presentation
• Diagnostic workup
• Treatment
• Patient education
• Prognosis and monitoring
• Special populations
• When to refer
• Smartphrase snippets
• Related pages

Definition and epidemiology#

Diagnostic criteria#

BPH is a clinical diagnosis based on:

• Lower urinary tract symptoms (LUTS) in a male patient
• Enlarged prostate on digital rectal exam (DRE) or imaging
• Exclusion of other causes (UTI, prostate cancer, neurogenic bladder, urethral stricture)

AUA Symptom Index (AUA-SI) / International Prostate Symptom Score (IPSS):

• 7-question validated questionnaire (score 0-35)
• Mild: 0-7 (watchful waiting often appropriate)
• Moderate: 8-19 (medical therapy indicated if bothersome)
• Severe: 20-35 (medical therapy; consider surgical referral)
• Plus quality of life question (0-6): “If you were to spend the rest of your life with your urinary condition the way it is now, how would you feel?”

Symptom categories:

• Storage (irritative): frequency, urgency, nocturia, urge incontinence
• Voiding (obstructive): hesitancy, weak stream, straining, intermittency, incomplete emptying, post-void dribbling

Epidemiology#

Histologic BPH present in 50% of men by age 50, 90% by age 80. Symptomatic BPH affects approximately 50% of men over 50. Risk factors include age (strongest), family history, obesity, diabetes, and metabolic syndrome. Black and Hispanic men have higher rates of symptomatic BPH. Protective factors include physical activity and moderate alcohol consumption.

Pathophysiology#

Mechanism (clinical understanding)#

Prostatic enlargement: BPH involves hyperplasia of stromal and epithelial cells in the transition zone of the prostate (surrounding the urethra). This is driven by dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase. The enlarged prostate compresses the urethra, causing mechanical obstruction.

Two components of obstruction:

1. Static component: Physical enlargement of the gland compressing the urethra—targeted by 5-alpha reductase inhibitors (shrink the gland)
2. Dynamic component: Smooth muscle tone in the prostate and bladder neck mediated by alpha-1 adrenergic receptors—targeted by alpha-blockers (relax smooth muscle)

Bladder response to obstruction: Chronic obstruction leads to detrusor muscle hypertrophy (compensatory) followed by detrusor decompensation. This explains why some patients have persistent symptoms even after relieving obstruction—the bladder has been damaged.

Why symptoms don’t always correlate with prostate size: Small prostates can cause significant obstruction if the enlargement is periurethral. Large prostates may cause minimal symptoms if growth is peripheral. This is why treatment is based on symptoms, not prostate size alone.

How to explain to patients#

Your prostate is a walnut-sized gland that sits below your bladder and surrounds the tube that carries urine out (the urethra). As men age, the prostate grows larger—this is normal and not cancer.

The problem is that as the prostate grows, it squeezes the urethra like a clamp on a garden hose. This makes it harder to urinate and can cause you to go more often, especially at night.

The good news is that BPH is very common and very treatable. Medications can relax the prostate muscle to improve flow quickly, or shrink the prostate over time. Most men get significant relief with treatment.

Clinical presentation#

Characteristic symptoms#

Voiding (obstructive) symptoms:

• Hesitancy: difficulty starting urination; standing and waiting
• Weak stream: reduced force of urinary stream
• Straining: need to push or bear down to urinate
• Intermittency: stream starts and stops
• Incomplete emptying: sensation of residual urine after voiding
• Post-void dribbling: continued dribbling after finishing

Storage (irritative) symptoms:

• Frequency: voiding more than 8 times per day
• Nocturia: waking 2 or more times per night to urinate
• Urgency: sudden compelling need to void
• Urge incontinence: leakage associated with urgency

Symptom patterns:

• Symptoms typically develop gradually over years
• Nocturia is often the most bothersome symptom
• Symptoms may fluctuate (worse with cold, decongestants, alcohol, caffeine)
• Acute urinary retention can be the first presentation (often precipitated by medications, surgery, or infection)

Physical exam findings#

Digital rectal exam (DRE):

• Prostate size: normal ~20g (walnut); enlarged may be 30-100g+
• Consistency: BPH is smooth, rubbery, symmetric
• Median sulcus: may be obliterated with significant enlargement
• Nodules, asymmetry, induration: concerning for cancer—requires further evaluation

Abdominal exam:

• Palpable bladder: suggests significant retention (bladder normally not palpable)
• Suprapubic fullness or tenderness

Focused neurologic exam (if neurogenic bladder suspected):

• Perineal sensation (S2-S4)
• Lower extremity reflexes
• Anal tone

Red flags#

• Acute urinary retention: inability to void with palpable bladder—needs catheterization
• Recurrent UTIs: suggests significant residual urine
• Gross hematuria: requires malignancy workup regardless of BPH
• Elevated creatinine: suggests obstructive uropathy
• Abnormal DRE (nodule, asymmetry, induration): prostate cancer evaluation needed
• Rapidly progressive symptoms: consider cancer or neurologic cause
• New neurologic symptoms (saddle anesthesia, leg weakness): cauda equina syndrome

Diagnostic workup#

Initial evaluation#

All patients with LUTS:

• AUA Symptom Index (AUA-SI): quantify severity (0-35); repeat to track response
• Urinalysis: rule out UTI, hematuria, glucosuria (diabetes causing polyuria)
• Digital rectal exam: assess prostate size, consistency, nodules
• Serum creatinine: if retention suspected or baseline renal function unknown

PSA testing:

• Discuss risks/benefits before ordering (shared decision-making)
• Reasonable if life expectancy >10 years and patient would pursue treatment if cancer found
• BPH elevates PSA (~0.3 ng/mL per gram of prostate tissue)
• PSA >4 ng/mL or rapidly rising warrants urology referral
• 5-ARIs reduce PSA by ~50%—must double the value for cancer screening

Post-void residual (PVR):

• Bladder scan or catheterization after voiding
• Normal: <50 mL; elevated: >200 mL suggests significant retention
• Check before starting anticholinergics (if OAB component) and after starting 5-ARIs
• Elevated PVR increases UTI risk and may indicate need for surgical intervention

Confirmatory testing#

Usually not needed for straightforward BPH. Consider if:

Uroflowmetry:

• Measures peak urinary flow rate (Qmax)
• Normal: >15 mL/sec; obstructed: <10 mL/sec
• Available in urology offices; not typically done in primary care
• Useful for surgical planning and monitoring treatment response

Prostate ultrasound (transrectal or abdominal):

• Accurate prostate volume measurement
• Guides 5-ARI use (most beneficial if prostate >30-40g)
• Not routine; order if DRE inconclusive or planning 5-ARI therapy

Cystoscopy:

• Direct visualization of urethra and bladder
• Indicated for: hematuria workup, suspected stricture, prior urethral surgery, surgical planning
• Not routine for uncomplicated BPH

Urodynamic studies:

• Pressure-flow studies to confirm obstruction vs detrusor weakness
• Reserved for complex cases, prior failed surgery, or neurogenic bladder suspected
• Ordered by urology, not primary care

When to refer for specialist workup#

• Abnormal DRE (nodule, asymmetry, induration)
• Elevated or rising PSA concerning for cancer
• Hematuria requiring cystoscopy
• Elevated PVR (>200-300 mL) despite medical therapy
• Suspected neurogenic bladder
• Failed medical therapy
• Considering surgical intervention

What NOT to order#

• Routine prostate ultrasound for uncomplicated BPH—DRE is sufficient for most patients
• Cystoscopy without specific indication (hematuria, stricture concern, surgical planning)
• Urodynamics in primary care—this is a urology test for complex cases
• PSA without discussion—requires shared decision-making about implications
• CT or MRI for routine BPH evaluation—not indicated

Treatment#

Goals of therapy#

• Symptom relief: reduce AUA-SI score by ≥3 points (clinically meaningful)
• Improve quality of life: reduce bother from urinary symptoms
• Prevent complications: urinary retention, UTIs, bladder stones, renal insufficiency
• Avoid unnecessary intervention: watchful waiting appropriate for mild symptoms

Treatment thresholds:

• Mild symptoms (AUA-SI 0-7): watchful waiting; behavioral modifications
• Moderate symptoms (AUA-SI 8-19): medical therapy if bothersome
• Severe symptoms (AUA-SI 20-35): medical therapy; consider surgical referral

Non-pharmacologic management#

Behavioral modifications (first-line for all patients):

Medications to avoid or use cautiously:

• Decongestants (pseudoephedrine): alpha-agonist effect worsens obstruction
• Antihistamines (diphenhydramine, first-generation): anticholinergic effect impairs bladder contraction
• Anticholinergics (oxybutynin, tolterodine): can precipitate retention if significant obstruction
• Opioids: reduce detrusor contractility
• Diuretics: increase urine volume; time dosing to avoid nocturia

Pharmacologic management#

Alpha-blockers (first-line for most patients):

5-Alpha reductase inhibitors (for prostate >30-40g):

Combination therapy:

• Alpha-blocker + 5-ARI: For prostate >30-40g with moderate-severe symptoms; more effective than monotherapy for preventing progression (MTOPS, CombAT trials)
• Alpha-blocker + anticholinergic: For significant OAB component with obstruction; use cautiously; check PVR; avoid if PVR >200 mL

PDE5 inhibitor (alternative/adjunct):

Patient counseling points#

For alpha-blockers:

• “This medication relaxes the muscle in your prostate and bladder neck. You should notice improvement in your stream within a few days to 2 weeks.”
• “Take it at bedtime to reduce dizziness. Rise slowly from sitting or lying down, especially at first.”
• “You may experience ‘dry orgasm’ (ejaculation without fluid)—this is not harmful but can be bothersome. Let me know if it’s a problem.”
• “If you’re planning cataract surgery, tell your eye doctor you’re on this medication—it can affect the surgery.”

For 5-ARIs:

• “This medication shrinks your prostate over time. It takes 6-12 months to see the full benefit, so be patient.”
• “It reduces your PSA by about half. We’ll account for this when checking for prostate cancer.”
• “Side effects can include decreased sex drive, erectile problems, and decreased ejaculate volume. These affect about 5-10% of men.”
• “Do not let pregnant women handle crushed or broken tablets—it can harm a developing baby.”

For combination therapy:

• “We’re using two medications that work differently—one for quick relief and one to shrink the prostate over time.”
• “You may be able to stop the alpha-blocker after 6-12 months once the prostate has shrunk.”

Monitoring and follow-up#

Initial phase:

• Follow-up in 4-6 weeks after starting alpha-blocker to assess response
• Follow-up in 3-6 months after starting 5-ARI (takes longer to work)
• Repeat AUA-SI to quantify improvement
• Check PVR if symptoms not improving or worsening

Stable phase:

• Annual follow-up with AUA-SI
• Annual DRE
• PSA per shared decision-making (remember to double value if on 5-ARI)
• PVR if symptoms change

Monitoring parameters:

Patient education#

What is this condition?#

BPH stands for benign prostatic hyperplasia. It means your prostate gland has grown larger. This is very common as men get older—about half of men over 50 have it.

Your prostate sits below your bladder and surrounds the tube that carries urine out of your body. When the prostate grows, it can squeeze this tube and make it harder to urinate.

BPH is not cancer and does not turn into cancer. However, you can have both BPH and prostate cancer at the same time, which is why we still do screening tests.

What you can do#

Limit fluids in the evening. Stop drinking 2-3 hours before bedtime to reduce nighttime trips to the bathroom.

Cut back on caffeine and alcohol. These irritate the bladder and make you urinate more often.

Avoid cold medicines with decongestants (like Sudafed). These can make it much harder to urinate and can even cause you to be unable to urinate at all.

Try double voiding. After you finish urinating, wait 30 seconds and try again. This helps empty your bladder more completely.

Do not rush. Take your time when urinating. Straining or pushing can make things worse over time.

Take your medications as prescribed. Alpha-blockers work within days to weeks. Medications that shrink the prostate take 6-12 months to work fully.

When to seek care#

Call your doctor if you cannot urinate at all. This is an emergency that needs immediate treatment.

Call your doctor if you see blood in your urine.

Call your doctor if you have fever with urinary symptoms. This could be an infection.

Call your doctor if your symptoms are getting significantly worse despite treatment.

Call your doctor if you have new back pain, leg weakness, or numbness in your groin area.

Questions to ask your doctor#

How large is my prostate? Do I need medication to shrink it, or just to relax it?

Should I have a PSA test? What are the pros and cons?

Are any of my current medications making my symptoms worse?

What symptoms should make me call you right away?

At what point should I consider surgery?

Prognosis and monitoring#

Expected course#

Natural history (untreated):

• Symptoms progress in about 30-40% of men over 4-5 years
• Acute urinary retention occurs in 1-2% per year
• Spontaneous improvement occurs in 15-30% (fluctuating course)

With medical therapy:

• Alpha-blockers: 30-40% improvement in AUA-SI within 2-4 weeks; effect maintained long-term
• 5-ARIs: 20-30% reduction in prostate volume over 6-12 months; 50% reduction in retention and surgery risk
• Combination therapy: superior to monotherapy for preventing progression in men with large prostates

Factors predicting progression:

• Prostate volume >30g
• PSA >1.5 ng/mL
• Age >70
• Moderate-severe symptoms at baseline
• Low peak flow rate (<10 mL/sec)

Monitoring parameters#

Complications to watch for#

Acute urinary retention:

• Inability to void despite full bladder
• Often precipitated by medications (decongestants, anticholinergics), surgery, anesthesia, or infection
• Requires catheterization; trial of voiding after alpha-blocker therapy
• 50-70% can void successfully after catheter removal with alpha-blocker

Recurrent UTIs:

• Due to incomplete bladder emptying (residual urine)
• Evaluate PVR; consider surgical intervention if recurrent

Bladder stones:

• Form in stagnant residual urine
• Present with intermittent obstruction, hematuria, recurrent UTI
• Require surgical removal

Obstructive uropathy:

• Chronic retention leads to hydronephrosis and renal insufficiency
• Monitor creatinine; urgent urology referral if present

Bladder decompensation:

• Chronic obstruction damages detrusor muscle
• May have persistent symptoms even after relieving obstruction
• Reason to treat earlier rather than waiting for severe symptoms

Special populations#

Elderly/geriatric#

Treatment considerations:

• BPH prevalence increases with age; treatment still beneficial in elderly
• Higher sensitivity to orthostatic hypotension from alpha-blockers
• Start with uroselective agents (tamsulosin, silodosin, alfuzosin)
• Avoid doxazosin and terazosin as first-line (more orthostasis, falls risk)
• 5-ARIs well-tolerated in elderly; sexual side effects may be less concerning

Beers criteria considerations:

• Doxazosin and terazosin: avoid as first-line for BPH due to orthostatic hypotension and falls risk
• If alpha-blocker needed, use tamsulosin or alfuzosin (more uroselective)

Dose adjustments:

• Tamsulosin: no adjustment needed
• Alfuzosin: use with caution; avoid if severe hepatic impairment
• Silodosin: reduce to 4 mg daily if CrCl 30-50; avoid if CrCl <30

Polypharmacy considerations:

• Review all medications for anticholinergic burden
• Avoid combining alpha-blockers with other hypotensive agents if possible
• Watch for drug interactions with CYP3A4 inhibitors (increase alfuzosin levels)

Chronic kidney disease#

Monitoring:

• Check creatinine at baseline and if symptoms worsen
• Elevated creatinine may indicate obstructive uropathy—urgent urology referral
• PVR monitoring more important in CKD (retention worsens renal function)

Medication adjustments:

Special considerations:

• Obstructive uropathy from BPH can cause or worsen CKD
• Relieving obstruction may improve renal function
• Lower threshold for urology referral in CKD patients

Other populations#

Cardiovascular disease:

• Alpha-blockers can lower BP—may be beneficial in hypertensive patients
• Avoid combining alpha-blockers with PDE5 inhibitors initially (hypotension risk)
• If using tadalafil for BPH, start alpha-blocker at lowest dose or use tamsulosin (least interaction)

Diabetes:

• Higher prevalence of BPH in diabetic men
• Diabetic cystopathy may coexist (neurogenic component)
• Monitor PVR more closely
• Consider urology referral earlier if poor response to medical therapy

Patients planning cataract surgery:

• Alpha-blockers cause intraoperative floppy iris syndrome (IFIS)
• Inform ophthalmologist of alpha-blocker use (current or past)
• Do NOT stop alpha-blocker before surgery—IFIS risk persists
• Ophthalmologist can take precautions if aware

Sexual function concerns:

• Discuss retrograde ejaculation risk with alpha-blockers (especially silodosin)
• Discuss sexual side effects of 5-ARIs (decreased libido, ED in 5-10%)
• Tadalafil 5mg daily treats both BPH and ED
• Avoid combining tadalafil with alpha-blockers initially

When to refer#

Specialist referral criteria#

Urology referral indications:

Urgency levels#

Smartphrase snippets#

BPH, stable on medical therapy: BPH with AUA-SI [X], improved from baseline. Tolerating tamsulosin 0.4 mg without orthostasis; PVR [X] mL. Continue current regimen; f/u annually.

BPH, starting alpha-blocker: BPH with moderate LUTS (AUA-SI [X]); DRE enlarged, smooth, no nodules. Starting tamsulosin 0.4 mg daily; counseled on orthostatic precautions and IFIS risk. F/u 4-6 weeks.

BPH, adding 5-ARI: BPH with large prostate and moderate-severe symptoms despite alpha-blocker. Adding finasteride 5 mg daily; counseled on 6-12 month onset and PSA reduction. F/u 3-6 months.

BPH, urology referral: BPH with [indication]; referring to urology for evaluation. Continue current medications pending evaluation.

Related pages#

• Urinary Frequency/Urgency (complaint) — symptom-based approach to LUTS differential
• Hematuria (complaint) — BPH can cause hematuria; requires malignancy workup
• Dysuria (complaint) — male UTI section; BPH increases UTI risk
• Erectile Dysfunction (complaint) — tadalafil treats both BPH and ED
• Chronic Kidney Disease (problem) — obstructive uropathy from BPH can cause CKD